{"title":"复发/难治性多发性骨髓瘤，DLBCL和CLL: 2023 ASCO年度会议的高级从业者重点","authors":"Oxana Megherea, PharmD, BCOP","doi":"10.6004/jadpro.2023.14.6.11","DOIUrl":null,"url":null,"abstract":"Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner\",\"authors\":\"Oxana Megherea, PharmD, BCOP\",\"doi\":\"10.6004/jadpro.2023.14.6.11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.\",\"PeriodicalId\":17176,\"journal\":{\"name\":\"Journal of the Advanced Practitioner in Oncology\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Advanced Practitioner in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.6.11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.6.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner
Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
